PTC Therapeutics: director Michael Schmertzler sold 2,500 shares

What happened

• Michael Schmertzler, a director, sold 2,500 shares of PTC Therapeutics common stock in two open-market transactions on Oct 7, 2026 for a total of $158,480.
• The filing lists a sale of 2,447 shares at $63.38 for $155,091 and a sale of 53 shares at $63.95 for $3,389.

Key details

• Transaction date(s) and price(s): Oct 7, 2026 — 2,447 shares at $63.38 ($155,091) and 53 shares at $63.95 ($3,389).
• The $63.38 price is reported as a weighted average of multiple trades executed at prices ranging from $62.89 to $63.88 per share; the filer says it can provide a breakdown on request.
• The sales were effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., on May 14, 2026.
• The shares sold represent shares held by Section Six Partners, L.P.; Schmertzler is a general and limited partner of Section Six Partners, L.P., and disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
• Shares owned following the transactions are not stated in the filing.

Why it may matter

• These were open-market sales executed under a Rule 10b5-1 plan, not option exercises or gifts.
• The filing does not show why the insider traded or why the company acted.